The resurrection of alphafetoprotein

Journal of Hepatology

Volumn 52, Issue 6, 2010, Pages 939-940

  Sherman, Morris ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Alphafetoprotein; Hepatocellular carcinoma

Indexed keywords

ALPHA FETOPROTEIN; TUMOR MARKER;

ARTICLE; ARTIFICIAL EMBOLISM; CANCER SURVIVAL; CHEMOEMBOLIZATION; DIAGNOSTIC TEST; HUMAN; LIVER CELL CARCINOMA; LIVER FAILURE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RADIOEMBOLIZATION; RISK ASSESSMENT; TREATMENT RESPONSE;

EID: 77952423583     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.02.006     Document Type: Note

References (17)

1. Oka H., Tamori A., Kuroki T., Kobayashi K., and Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 19 (1994) 61-66
2. Zhang J.Y., Wang X., Han S.G., and Zhuang H. A case-control study of risk factors for hepatocellular carcinoma in Henan, China. Am J Trop Med Hyg 59 (1998) 947-951
3. Farinati F., Marino D., De Giorgio M., Baldan A., Cantarini M., Cursaro C., et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?. Am J Gastroenterol 101 (2006) 524-532
4. Rapaccini G.L., Pompili M., Caturelli E., Covino M., Lippi M.E., Beccaria S., et al. Hepatocellular carcinomas <2 cm in diameter complicating cirrhosis: ultrasound and clinical features in 153 consecutive patients. Liver Int 24 (2004) 124-130
5. Sherman M., Peltekian K.M., and Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 22 (1995) 432-438
6. Chung W.K., Sun H.S., Park D.H., Minuk G.Y., and Hoofnagle J.H. Primary hepatocellular carcinoma and hepatitis B virus infection in Korea. J Med Virol 11 (1983) 99-104
7. Koike Y., Shiratori Y., Sato S., Obi S., Teratani T., Imamura M., et al. Desgamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 91 (2001) 561-569
8. Carr B.I., Kanke F., Wise M., and Satomura S. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci 52 (2007) 776-782
9. Shetty K., Timmins K., Brensinger C., Furth E.E., Rattan S., Sun W., et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 10 (2004) 911-918
10. Sherman M. Alphafetoprotein: an obituary. J Hepatol 34 (2001) 603-605
11. Trevisani F., D'Intino P.E., Morselli-Labate A.M., Mazzella G., Accogli E., Caraceni P., et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 34 (2001) 570-575
12. Lok A.S., Sterling R.K., Everhart J.E., Wright E.C., Hoefs J.C., Di Bisceglie A.M., et al. Des-gamma-carboxy prothrombin and alpha fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) [Epub Sept 2009]
13. Chan S.L., Mo F.K., Johnson P.J., Hui E.P., Ma B.B., Ho W.M., et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 27 (2009) 446-452 [Epub 2008 Dec 8]
14. Riaz A., Ryu R.K., Kulik L.M., Mulcahy M.F., Lewandowski R.J., Minocha J., et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol 27 (2009) 5734-5742 [Epub 2009 Oct 5]
15. Chen L.T., Shiah H.S., Chao Y., Chang J.Y., Cheng L.T., and Whang-Peng J. Alpha-fetoprotein response in advanced hepatocellular carcinoma receiving cytostatic agent. J Clin Oncol 27 (2009) e271 author reply e272. [Epub 2009 Nov 16]
16. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
17. Cheng A.L., Kang Y.K., Chen Z., Tsao C.J., Qin S., Kim J.S., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10 (2009) 25-34